As ImClone Investigation Continues, FDA Combines Drugs, Biologics Review; Memo Describes “Lengthy Process” That Led To FDA Decision; Oncology Community Praises FDA Move
ASCO, NCCS Call For Oncology Center
Zerhouni Appoints Two Institute Directors
ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard
NCI Program Develops Bioinformatics Tool To Design Cancer Drugs
